Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:09 PM ET 8-K
Reverse Stock Split Treasure Global Inc TGL

Treasure Global Reverse Stock Split

Treasure Global Inc. implemented a 1-for-24 reverse stock split of its common stock effective November 16, 2026. The action is primarily intended to increase the per-share trading price to regain compliance with the Nasdaq minimum bid price requirement of $1.00 per share. The split reduced the company's outstanding shares from approximately 22 million to approximately 0.9 million.

4:09 PM ET 8-K
M&A Deal Aytu Biopharma, Inc AYTU

Aytu Biopharma M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.

Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals for $2.70 per share in an all-cash tender offer. The deal represents a 51.7% premium to Aytu's closing price on November 13, 2026, and is expected to close by the end of 2026. Upon completion, Aytu will become a wholly owned subsidiary of Rosemont, supporting Rosemont's U.S. growth strategy in the CNS and pediatric specialty pharmaceutical markets.

Counterparty
Rosemont Pharmaceuticals Holdings, Inc.
4:09 PM ET 8-K
Investor Presentation Public Storage PSA

Public Storage Investor Presentation

Public Storage announced that it has posted an investor presentation to its website on November 16, 2026. The company intends to use this presentation at an upcoming investor conference to provide strategic and operational updates to the market.

4:09 PM ET 8-K
Business Update Cardlytics, Inc. CDLX

Cardlytics Business Update

Cardlytics announced a workforce reduction of approximately 30 employees, or 15% of its staff, as part of a broader cost-reduction initiative. The company expects to incur $0.7 million in non-recurring severance charges while achieving approximately $12.2 million in annualized operating expense savings. The restructuring is expected to be substantially complete by the end of the fourth quarter of 2026.

4:09 PM ET 8-K
Stock Buyback Keros Therapeutics, Inc. KROS

Keros Therapeutics Announces $5M Stock Buyback

Keros Therapeutics announced that its Board of Directors approved a new $5 million share repurchase program for its common stock. The buyback authorization follows the company's receipt of a $20 million development milestone payment from Takeda Pharmaceuticals related to the clinical trial dosing of elritercept. Keros expects its current cash reserves, including this milestone, to fund operations into 2029.

Value
$5M
4:09 PM ET 10-Q
Financial Results 374Water Inc. SCWO

374Water Q3 2026 Results: Net Loss of $3.26M, Loss Narrows

374Water Inc. reported a significant revenue increase to $3.47 million for the nine months ended September 30, 2026, compared to $1.90 million in the prior year period. Despite improved gross margins, the company incurred a net loss of $10.53 million due to high operating expenses and a $1.02 million loss on debt extinguishment.

Key figure
Net loss $3.26M
4:09 PM ET 10-Q
Financial Results Sbig Holdings, Inc. SBIG

Sbig Holdings Q3 2026 Results: Net Income $3.21M, Up 1366.7% YoY

SBIG Holdings, Inc. reported a net income of $3.2 million for the quarter ended September 30, 2026, primarily driven by a $1.7 million gain from discontinued operations and a $1.6 million gain on troubled debt restructuring. The company transferred its operating subsidiary, SpringBig, Inc., in July 2026 and currently has no operating business or revenue as it seeks a strategic transaction.

Key figure
Net income $3.21M · +1366.7% YoY
4:09 PM ET 8-K
Financial Results Acrivon Therapeutics, Inc. ACRV

Acrivon Therapeutics Financial Results

Acrivon Therapeutics reported Q3 2026 financial results, ending the period with $77.8 million in cash and marketable securities, which is expected to fund operations into Q4 2027. The company highlighted its strategic expansion into immunology and inflammation (I&I) with the acquisition of ACR-525 and provided updates on its clinical pipeline, including upcoming Phase 2b interim data for ACR-368.

Term
Q3 2026

“We have had transformative progress this year, including the strategic expansion into immunology and inflammation and the positive clinical results in tumor types predicted sensitive by AP3 to our internally developed, first-in-class WEE1/PKMYT1 inhibitor ACR-2316, laying the foundation for multiple upcoming value-inflection milestones.”

Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon
4:09 PM ET 10-Q
Financial Results FS Credit Real Estate Income Trust, Inc.

FS Credit Real Estate Income Trust Q3 2026 Results: Net Income $30.3M, Down 49.4% YoY

For the nine months ended September 30, 2026, FS Credit Real Estate Income Trust reported net income of $98.8 million, a decrease from $129.6 million in the prior year period. Total assets decreased to $11.4 billion from $11.8 billion at year-end 2025, primarily driven by a reduction in mortgage loans held in securitization trusts.

Key figure
Net income $30.3M · -49.4% YoY
4:09 PM ET 10-Q
Financial Results First Breach, Inc. FBDT

First Breach Q3 2026 Results: Net Loss of $25.3M, Loss Widens

First Breach, Inc. reported a significant increase in net loss to $53.8 million for the nine months ended September 30, 2026, driven by a surge in selling, general, and administrative expenses and stock-based compensation. Despite revenue growth to $0.93 million, the company maintains a negative gross margin and is currently operating as an early-stage, pre-net income entity.

Key figure
Net loss $25.3M
4:09 PM ET 10-Q
Financial Results International Land Alliance Inc. ILAL

International Land Alliance Q3 2026 Results: Net Loss of $1.57M, Loss Narrows

International Land Alliance Inc. reported net revenues of $2.20 million for the nine months ended September 30, 2026, but incurred a net loss of $8.27 million due to high general and administrative expenses and interest costs. The company's total assets remained stable at approximately $32.36 million, while stockholders' equity increased to $8.85 million following significant common stock issuances and debt conversions.

Key figure
Net loss $1.57M
4:09 PM ET Form 4
Insider Selling Nasdaq, Inc. NDAQ

Nasdaq EVP, CIO Bradley J. Peterson Sells $545K of Stock

Bradley J. Peterson, EVP, CIO, sold 5,000 shares of Nasdaq, Inc. at $109.07 a share, worth $545K in total on Nov 12, 2026. Shares held after the trade: 104,306 (-4.6%).

Value
$545K
Shares
5,000
Price
$109.07
Role
EVP, CIO
Holding change
-4.6%
Trade date
Nov 12, 2026
4:09 PM ET Form 4
Insider Selling Lifevantage Corp LFVN

Lifevantage Director Michael A. Beindorff Sells $48.9K of Stock

Michael A. Beindorff, Director, sold 10,000 shares of Lifevantage Corp at $4.89 a share, worth $48.9K in total on Nov 12, 2026. Shares held after the trade: 31,625 (-24.0%).

Value
$48.9K
Shares
10,000
Price
$4.89
Role
Director
Holding change
-24.0%
Trade date
Nov 12, 2026
4:09 PM ET Form 4
Insider Selling Dyne Therapeutics, Inc. DYN

Dyne Therapeutics CFO Erick Lucera Sells $33.5K of Stock

Erick Lucera, CFO, sold 1,991 shares of Dyne Therapeutics, Inc. at $16.82 a share, worth $33.5K in total on Nov 13, 2026. Shares held after the trade: 117,775 (-1.7%).

Value
$33.5K
Shares
1,991
Price
$16.82
Role
CFO
Holding change
-1.7%
Trade date
Nov 13, 2026
4:09 PM ET Form 4
Insider Selling Aflac Inc AFL

Aflac Insider Japan Post Holdings Co. Ltd. Sells $1.64M of Stock

Japan Post Holdings Co. Ltd. sold 12,900 shares of Aflac Inc at $126.76 to $129.08 a share (average $126.99) in 3 transactions, worth $1.64M in total on Nov 12, 2026. Shares held after the trade: 50,095,429 (-0.0%).

Value
$1.64M
Shares
12,900
Average price
$126.99
Holding change
-0.0%
Trade date
Nov 12, 2026
4:09 PM ET Form 4
Insider Selling Fennec Pharmaceuticals Inc. FENC

Fennec Pharmaceuticals Director Marco Maria Brughera Sells $240K of Stock

Marco Maria Brughera, Director, sold 20,000 shares of Fennec Pharmaceuticals Inc. at $12.00 a share, worth $240K in total on Nov 13, 2026. Shares held after the trade: 0 (-100.0%).

Value
$240K
Shares
20,000
Price
$12.00
Role
Director
Holding change
-100.0%
Trade date
Nov 13, 2026
4:09 PM ET Form 4
Insider Selling TheRealReal, Inc. REAL

TheRealReal CAO Steve Ming Lo Sells $1.04M of Stock

Steve Ming Lo, CAO, sold 73,298 shares of TheRealReal, Inc. at $14.20 to $14.27 a share (average $14.23) in 2 transactions, worth $1.04M in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 83,542 (-30.2%).

Value
$1.04M
Shares
73,298
Average price
$14.23
Role
CAO
Holding change
-30.2%
Trade date
Nov 12, 2026 to Nov 13, 2026
4:09 PM ET Form 4
Insider Selling Concentra Group Holdings Parent, Inc. CON

Concentra Group Holdings Parent Insider Greg M. Gilbert Sells $781K of Stock

Greg M. Gilbert sold 18,194 shares of Concentra Group Holdings Parent, Inc. at $42.90 a share, worth $781K in total on Nov 12, 2026. Shares held after the trade: 130,640 (-12.2%).

Value
$781K
Shares
18,194
Price
$42.90
Holding change
-12.2%
Trade date
Nov 12, 2026
4:08 PM ET 10-Q
Financial Results Soluna Holdings, Inc SLNH ▶ Call

Soluna Holdings Q3 2026 Results: Net Loss of $28.7M, Loss Widens

Soluna Holdings, Inc. is a non-accelerated filer and smaller reporting company focused on Bitcoin mining and high-performance computing (HPC) data centers. As of November 12, 2026, the company reported 258,827,640 shares of common stock outstanding and is expanding its services into GPU-as-a-Service and AI-related infrastructure.

Key figure
Net loss $28.7M
4:08 PM ET 10-Q
Financial Results VirnetX Holding Corp VHC

VirnetX Holding Q3 2026 Results: Net Loss of $4.51M, Loss Widens

VirnetX Holding Corp reported zero revenue for the nine months ended September 30, 2026, and a net loss of $13.4 million. The company issued a going concern warning, stating that its current cash and cash equivalents of $10.1 million are insufficient to fund operations for the next twelve months.

Key figure
Net loss $4.51M
4:08 PM ET 10-Q
Financial Results Global Gas Corp HGAS

Global Gas Q3 2026 Results: Net Loss of $19.7K, Loss Narrows

Global Gas Corporation reported a net loss of $87,641 for the nine months ended September 30, 2026, compared to a loss of $21,844 in the prior year period. The company remains a nascent project developer with zero revenue in 2026 and a total stockholders' deficit of $383,971 as of the reporting date.

Key figure
Net loss $19.7K
4:08 PM ET 10-Q
Financial Results 5E Advanced Materials, Inc. FEAM

5E Advanced Materials Q1 2026 Results: Net Loss of $13.1M, Loss Widens

5E Advanced Materials, Inc. has transitioned from a pre-revenue development stage company to a revenue-generating producer following a recent acquisition. However, the company reports substantial doubt regarding its ability to continue as a going concern, citing the need for significant additional funding to maintain operations and advance the Fort Cady Project.

Key figure
Net loss $13.1M
4:08 PM ET 10-Q
Financial Results Entrepreneur Universe Bright Group EUBG

Entrepreneur Universe Bright Group Q3 2026 Results: Net Loss of $222K

Entrepreneur Universe Bright Group reported a net loss of $178,346 for the nine months ended September 30, 2026, compared to a net income of $1,001,450 in the prior year period, driven by a 35% decline in revenue. During the period, the company expanded into the Fintech sector through the acquisition of HengYing International Investment Limited and initiated commercial lending activities.

Key figure
Net loss $222K
4:08 PM ET 10-Q
Financial Results Dare Bioscience, Inc. DARE

Dare Bioscience Q3 2026 Results: Net Loss of $3.16M, Loss Narrows

For the nine months ended September 30, 2026, Dare Bioscience reported a net loss of $9.14 million, an improvement from the $11.96 million loss in the prior year period. The company expanded its business model to include a dual-path approach for market access via 503B outsourcing facilities while continuing traditional FDA approval pathways.

Key figure
Net loss $3.16M
4:08 PM ET 10-Q
Financial Results Pathfinder Bancorp, Inc. PBHC

Pathfinder Bancorp Q3 2026 Results: Net Income $2.07M, Up 230.5% YoY

For the nine months ended September 30, 2026, Pathfinder Bancorp reported net income of $7.15 million, a significant increase from $3.63 million in the prior year period, primarily driven by a $5.1 million reduction in the provision for credit losses. Total assets grew to $1.49 billion, while shareholders' equity decreased slightly to $118.8 million due to an increase in accumulated other comprehensive loss from available-for-sale securities.

Key figure
Net income $2.07M · +230.5% YoY
4:08 PM ET 10-Q
Financial Results Cycurion, Inc. CYCU

Cycurion Q3 2026 Results: Net Loss of $2.92M, Loss Narrows

Cycurion, Inc. reported revenue of $12.4 million for the nine months ended September 30, 2026, compared to $11.6 million in the prior year period. The company significantly reduced its operating loss to $7.2 million from $18.4 million year-over-year, primarily due to the absence of one-time business combination expenses incurred in 2025.

Key figure
Net loss $2.92M
4:08 PM ET 10-Q
Financial Results Security Midwest Bancorp, Inc. SBMW

Security Midwest Bancorp Q3 2026 Results: Net Income $445K, Up 58.2% YoY

Security Midwest Bancorp reported net income of $1.25 million for the nine months ended September 30, 2026, an increase from $1.03 million in the prior year period. The company experienced significant loan growth, with net loans increasing to $137.0 million from $117.8 million at year-end 2025, while total assets remained stable at approximately $255.9 million.

Key figure
Net income $445K · +58.2% YoY
4:08 PM ET 10-Q
Financial Results Acrivon Therapeutics, Inc. ACRV

Acrivon Therapeutics Q3 2026 Results: Net Loss of $17.9M, Loss Narrows

For the nine months ended September 30, 2026, Acrivon Therapeutics reported a net loss of $54.9 million, a slight improvement from the $58.9 million loss in the prior year period. The company's cash position decreased to $47.5 million from $41.5 million at year-end 2025, while short-term investments dropped significantly from $77.1 million to $30.2 million.

Key figure
Net loss $17.9M
4:08 PM ET 10-Q
Financial Results Zoned Properties, Inc. ZDPY

Zoned Properties Q3 2026 Results: Net Income $5.31M, Up 3320.0% YoY

Zoned Properties reported a significant increase in net income to $5.33 million for the nine months ended September 30, 2026, primarily driven by a $5.91 million gain from the sale of rental properties classified as discontinued operations. The company's cash position strengthened substantially to $10.46 million, while continuing operations remained pre-revenue with an operating loss of $1.12 million.

Key figure
Net income $5.31M · +3320.0% YoY
4:08 PM ET 10-Q
Financial Results Myseum.AI, Inc. MYSE

Myseum.AI Q3 2026 Results: Net Loss of $1.95M, Loss Widens

Myseum.AI, Inc. reported a significant net loss of $7.87 million for the nine months ended September 30, 2026, compared to a $4.21 million loss in the prior year, driven by increased operating expenses and a $2.58 million unrealized loss on non-traded equity securities. Total assets decreased from $7.20 million to $3.59 million during the period, primarily due to the devaluation of investments and cash burn from operations.

Key figure
Net loss $1.95M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.